How much revenue does Shenzhen Weiguang Biological Products make?

Shenzhen Weiguang Biological Products reported 1.27 billion CNY in revenue for fiscal year 2025, up 5.3% from 1.20 billion CNY in fiscal year 2024. In Q1 2026 revenue was 221.87 million CNY.

What is Shenzhen Weiguang Biological Products's largest business segment?

Blood Products, with 1.11 billion CNY or 89% of segment revenue in fiscal year 2025. Next: Property Lease (11%).

What companies are similar to Shenzhen Weiguang Biological Products?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Luoxin Pharmaceuticals Group Stock Co., Ltd. (002793.SZ), Lionco Pharmaceutical Group Co.,Ltd. (603669.SS), Teyi Pharmaceutical Group Co.,Ltd (002728.SZ), Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ).

Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) Stock

About Shenzhen Weiguang Biological Products Co., Ltd.

Shenzhen Weiguang Biological Products Co., Ltd. engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection free...

At a glance

Shenzhen Weiguang Biological Products reported revenue of 1.27 billion CNY for fiscal year 2025, up 5.3% from fiscal year 2024, and net income of 246.32 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 221.87 million CNY, down 1.4% from a year before. Its largest business segment, Blood Products, brought in 89% of segment revenue in fiscal year 2025.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.